Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,624.70
(
-1.36%
)
US TECH 100
23,767.60
(
-1.51%
)
Dow Jones
46,225.15
(
-1.63%
)
Brent Oil
109.87
(
3.08%
)
Bitcoin
70,625.80
(
-0.86%
)
News Focus
News Focus
Post# of 257257
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 842
Posts 122795
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 162886

Friday, 10/25/2013 9:16:54 AM

Friday, October 25, 2013 9:16:54 AM

Post# of 257257
ABBV/ENTA—The multi-genotypic 2-DAA regimen of ENTA’s ABT-493 (PI) + ABBV’s in-house ABT-530 (NS5A) will enter phase-2 in 2014. (Source: ABBV’s CC today.)

Note: ENTA receives a higher royalty on this 2-DAA regimen than on the 3-DAA combination currently in phase-3.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now